Research
Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial
Nature ·
The Brief
- Published as a placebo-controlled randomized clinical trial on semaglutide in individuals with heart failure with preserved ejection fraction (HFpEF) and obesity.
- The study examines hemodynamic effects of semaglutide in this patient group.
- The only available source is a nature.com feed entry without a summary.
Why it matters
It adds randomized trial evidence on how semaglutide affects heart function measures in people with HFpEF and obesity, a population with limited treatment options.
Who’s affected
- Clinicians and researchers treating HFpEF with obesity
- #semaglutide
- #heart failure
- #hfpef
- #obesity
- #clinical trial
- #hemodynamics